These include Poly (ADP-ribose) polymerase (PARP) inhibitor for BRCA1/2-mutated or HRD ovarian carcinosarcoma [[26], [27], [28]], with evidence extrapolated from high-grade tubo-ovarian serous carcinoma and anti-Her-2 therapy to ERBB2/Her-2 amplified uterine carcinosarcoma, which is under clinical trial evaluation (NCT05256225) [29]. This evidence concerns the gene ERBB2 and ovarian serous carcinoma.